Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-3
Public ClinicalTrials.gov record NCT01984424. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Double-blind, Randomized, Multicenter Study to Evaluate the Safety and Efficacy of Evolocumab, Compared With Ezetimibe, in Hypercholesterolemic Subjects Unable to Tolerate an Effective Dose of a HMG-CoA Reductase Inhibitor Due to Muscle Related Side Effects
Study identification
- NCT ID
- NCT01984424
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Amgen
- Industry
- Enrollment
- 511 participants
Conditions and interventions
Conditions
Interventions
- Atorvastatin Drug
- Placebo to Atorvastatin Drug
- Placebo to Ezetimibe Other
- Ezetimibe Drug
- Placebo to Evolocumab Other
- Evolocumab Drug
Drug · Other
Eligibility (public fields only)
- Age range
- 18 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 9, 2013
- Primary completion
- Nov 9, 2015
- Completion
- Nov 20, 2017
- Last update posted
- Nov 28, 2018
2013 – 2017
United States locations
- U.S. sites
- 18
- U.S. states
- 14
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Beverly Hills | California | 90211 | — |
| Research Site | Huntington Beach | California | 92648 | — |
| Research Site | Los Angeles | California | 90048 | — |
| Research Site | San Pedro | California | 90732 | — |
| Research Site | Atlanta | Georgia | 30322 | — |
| Research Site | Sterling | Illinois | 61081 | — |
| Research Site | Kansas City | Kansas | 66160 | — |
| Research Site | Baltimore | Maryland | 21201 | — |
| Research Site | Towson | Maryland | 21204 | — |
| Research Site | Ann Arbor | Michigan | 48106 | — |
| Research Site | Rochester | Minnesota | 55905 | — |
| Research Site | St Louis | Missouri | 63110 | — |
| Research Site | New York | New York | 10029 | — |
| Research Site | Durham | North Carolina | 27710 | — |
| Research Site | Cleveland | Ohio | 44195 | — |
| Research Site | York | Pennsylvania | 17405 | — |
| Research Site | Charleston | South Carolina | 29425 | — |
| Research Site | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 40 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01984424, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 28, 2018 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01984424 live on ClinicalTrials.gov.